KR101018531B1 - 대잎둥굴레 또는 층층갈고리둥굴레 추출물을 유효성분으로 포함하는 비만 또는 대사 증후군 예방 및 치료용 조성물 - Google Patents
대잎둥굴레 또는 층층갈고리둥굴레 추출물을 유효성분으로 포함하는 비만 또는 대사 증후군 예방 및 치료용 조성물 Download PDFInfo
- Publication number
- KR101018531B1 KR101018531B1 KR1020100095987A KR20100095987A KR101018531B1 KR 101018531 B1 KR101018531 B1 KR 101018531B1 KR 1020100095987 A KR1020100095987 A KR 1020100095987A KR 20100095987 A KR20100095987 A KR 20100095987A KR 101018531 B1 KR101018531 B1 KR 101018531B1
- Authority
- KR
- South Korea
- Prior art keywords
- obesity
- group
- polygonatum
- metabolic syndrome
- extract
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 81
- 235000020824 obesity Nutrition 0.000 title claims abstract description 81
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 46
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 241000037831 Polygonatum sibiricum Species 0.000 title claims abstract description 14
- 241000037813 Polygonatum falcatum Species 0.000 title claims abstract description 10
- 239000004480 active ingredient Substances 0.000 title description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003208 petroleum Substances 0.000 claims abstract description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims abstract description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 4
- -1 spirit Substances 0.000 claims abstract description 4
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 claims abstract 3
- 229940093499 ethyl acetate Drugs 0.000 claims description 13
- 235000019439 ethyl acetate Nutrition 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000000579 abdominal fat Anatomy 0.000 abstract description 10
- 230000037396 body weight Effects 0.000 abstract description 9
- OPFTUNCRGUEPRZ-QLFBSQMISA-N Cyclohexane Natural products CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 abstract 1
- 235000009200 high fat diet Nutrition 0.000 description 66
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 42
- 108010041191 Sirtuin 1 Proteins 0.000 description 42
- 230000000694 effects Effects 0.000 description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 239000002024 ethyl acetate extract Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 235000019197 fats Nutrition 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 15
- 230000003579 anti-obesity Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 210000005228 liver tissue Anatomy 0.000 description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 12
- 229960004425 sibutramine Drugs 0.000 description 12
- 206010022489 Insulin Resistance Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 11
- 239000000469 ethanolic extract Substances 0.000 description 11
- 235000021590 normal diet Nutrition 0.000 description 11
- 235000021588 free fatty acids Nutrition 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000010171 animal model Methods 0.000 description 8
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000446313 Lamella Species 0.000 description 6
- 235000004347 Perilla Nutrition 0.000 description 6
- 244000124853 Perilla frutescens Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000401 methanolic extract Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229960003624 creatine Drugs 0.000 description 4
- 239000006046 creatine Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 208000004611 Abdominal Obesity Diseases 0.000 description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 3
- 235000017491 Bambusa tulda Nutrition 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 206010065941 Central obesity Diseases 0.000 description 3
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- 244000082204 Phyllostachys viridis Species 0.000 description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 3
- 102000011990 Sirtuin Human genes 0.000 description 3
- 108050002485 Sirtuin Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011425 bamboo Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 231100000191 repeated dose toxicity Toxicity 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 2
- 102100027441 Nucleobindin-2 Human genes 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000020805 dietary restrictions Nutrition 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000017525 heat dissipation Effects 0.000 description 2
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000037488 Coccoloba pubescens Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 101000709248 Homo sapiens NAD-dependent protein deacetylase sirtuin-7 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- 102100034376 NAD-dependent protein deacetylase sirtuin-7 Human genes 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 241000037815 Polygonatum lasianthum Species 0.000 description 1
- 241000037833 Polygonatum stenophyllum Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005813 organ abnormality Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
도 2는 대잎둥굴레 에틸아세테이트 추출물과 층층갈고리둥굴레 에틸아세테이트 추출물 투여에 의한 생쥐의 각 조직 내 SIRT1 발현 증가여부를 측정한 웨스턴 블롯 결과로 간, 지방과 근육조직 순으로 SIRT1의 발현을 측정한 것이다 (Vehicle: 음성 대조군).
도 3은 비만유도 동물모델에서 본 발명 조성물의 항비만 효과를 시험한 결과 중 생쥐의 체중을 시간별로 측정한 것이다. 수치는 9~10마리 쥐의 평균±표준편차 값이며 * 는 p<0.05, **는 p<0.01로 고지방식이와 비교하였을때 유의함을 의미한다 (□: 정상식이; ■: 고지방식이; ▲: 고지방식이+시부트라민 (100mg/kg사료); ●: 고지방식이+ID1216(5000mg/kg사료); ◆: 고지방식이+1215(5000mg/kg사료)).
도 4는 비만유도 동물모델에서 본 발명 조성물의 항비만 효과를 시험한 결과로, 간과 지방 조직의 무게를 측정한 그래프이다. 수치는 9~10마리 쥐의 평균±표준편차 값이며 * 는 p<0.05, **는 p<0.01로 고지방식이와 비교하였을때 유의함을 의미한다(ND: 정상식이군; HF:고지방식이군; Sibutramine: 고지방식이+시부트라민(100mg/kg사료); ID1216: 고지방식이+층층갈고리둥굴레 에틸아세테이트 추출물(5000mg/kg사료); ID1215: 고지방식이+대잎둥굴레 에틸아세테이트 추출물(5000mg/kg사료)).
도 5는 비만유도 동물모델에서 혈중 지질 농도를 측정한 결과이다. 도 5A는 혈중 콜레스테롤을, 도 5B는 혈중 중성지방을, 도 5C는 혈중 유리 지방산 농도를 고지방식이군과 비교한 도면이다 (ND: 정상식이군; HF:고지방식이군; Sibutramine: 고지방식이+시부트라민(100mg/kg사료); ID1216: 고지방식이+층층갈고리둥굴레 에틸아세테이트 추출물(5000mg/kg사료); ID1215: 고지방식이+대잎둥굴레 에틸아세테이트 추출물(5000mg/kg사료)).
도 6은 HEK 293 세포주에 대잎둥굴레와 층층갈고리둥굴레의 에탄올추출물과 에틸아세테이트 추출물을 각각 처리하여 SIRT1 단백질 발현 변화를 웨스턴 블롯(Western blot)으로 측정한 결과이다 (C: 음성대조군; ID1216: 층층갈고리둥굴레 에틸아세테이트 추출물; ID1215: 대잎둥굴레 에틸아세테이트 추출물, ID1216B: 층층갈고리둥굴레 80% 에탄올 추출물; ID1215B: 대잎둥굴레 80% 에탄올 추출물)
도 7은 비만유도 동물모델에서 본 발명 조성물의 항비만 효과를 시험한 결과 중 생쥐의 체중을 시간별로 측정한 것이다. 수치는 8마리 쥐의 평균±표준편차 값이며 * 는 p<0.05, **는 p<0.01로 고지방식이와 비교하였을때 유의함을 의미한다 (□: 정상식이; ■: 고지방식이; ◆: 고지방식이+ID1215B(250mg/kg); ▲: 고지방식이+ID1215B(500mg/kg); ●: 고지방식이+ID1215B(750mg/kg)).
도 8은 비만유도 동물모델에서 본 발명 조성물의 항비만 효과를 시험한 결과로, 간과 지방 조직의 무게를 측정한 그래프이다. 수치는 8 마리 쥐의 평균±표준편차 값이며 * 는 p<0.05, **는 p<0.01로 고지방식이와 비교하였을 때 유의함을 의미한다(ND: 정상식이군; HF:고지방식이군; 250mg/kg: 고지방식이+ID1215B-250mg/kg; 500mg/kg: 고지방식이+ID1215B-500mg/kg; 750mg/kg: 고지방식이+ID1215B-750mg/kg).
도 9는 비만 유도 동물모델에서, 본 발명 조성물의 항비만 효과와 관련된 저온시험(Cold test)결과이다. 수치는 8마리 쥐의 평균±표준편차 값이며 *는 p<0.05, **는 p<0.01로 고지방식이와 비교하였을때 유의함을 의미한다(■: 고지방식이; ◆: 고지방식이+ID1215B(250mg/kg); ▲: 고지방식이+ID1215B(500mg/kg); ●: 고지방식이+ID1215B(750mg/kg)).
도 10은 비만유도 동물모델에서 대사증후군 관련 효과를 시험한 결과이다. 도 10A는 글루코오스 경구투여에 의한 혈중 글루코오스 농도를 측정한 결과이다. 수치는 8 마리 쥐의 평균±표준편차 값이며 *는 p<0.05로 고지방식이와 비교하였을때 유의함을 의미한다(□: 정상식이; ■: 고지방식이; ◆: 고지방식이+ID1215B(250mg/kg); ▲: 고지방식이+ID1215B (500mg/kg); ●: 고지방식이+ID1215B(750mg/kg)). 도 10B는 비만식이군과 ID1215B 투여군의 8주 후 곡선하 면적(AUC, Area under curves)을 비교한 것이다.
도 11은 비만유도 동물모델에서 혈중 지질 농도를 측정한 결과이다. 도 11A는 혈중 콜레스테롤을, 도 11B는 혈중 중성지방을, 도 11C는 혈중 유리 지방산 농도를 고지방식이군과 비교한 도면이다 (ND: 정상식이군; HF:고지방식이군; 250mg/kg: 고지방식이+ID1215B-250 mg/kg; 500mg/kg: 고지방식이+ID1215B-500 mg/kg; 750mg/kg: 고지방식이+ID1215B-750 mg/kg).
도 12는 비만유도 동물모델에서 8주 후 간과 지방 조직을 광학 현미경으로 관찰하여 지방 및 간 세포 차이를 비교한 도면이다. 도 12A는 지방 세포의 크기 차이를 나타낸 도면이고, 도 12B는 간 세포의 상태 및 지방공포 정도를 보여주는 도면이다 (ND: 정상식이군; HF:고지방식이군; 250mg/kg: 고지방식이+ID1215B-250 mg/kg; 500mg/kg: 고지방식이+ID1215B-500 mg/kg; 750mg/kg: 고지방식이+ID1215B-750 mg/kg).
성분 | g/kg |
카제인(Casein) | 120 |
DL-메티오닌(DL-Methionine) | 1.8 |
옥수수 전분(Cornstarch) | 90 |
수크로오스(Sucrose) | 300 |
셀룰로오스(Cellulose) | 30 |
옥수수 기름(Corn Oil) | 30 |
염 혼합물(Salt Mix) | 21 |
비타민 혼합물(Vitamin Mix) | 6 |
타타르산수소콜린 (Choline Bitartrate) |
1.2 |
우지(Beef Tallow) | 400 |
%비율 | 간 | 지방 |
ND | 68.8 | 32.3 |
HF | 100.00 | 100.00 |
시부트라민 | 100.00 | 96.8 |
ID1216 | 93.8 | 96.8 |
ID1215 | 68.8 | 58.1 |
%비율 | 콜레스테롤 | 중성지방 | 유리지방산 |
ND | 52.6 | 55.7 | 53.2 |
HF | 100.00 | 100.00 | 100.00 |
시부트라민 | 112.2 | 89.7 | 96.4 |
ID1216 | 89.4 | 83.1 | 84.6 |
ID1215 | 72.2 | 73.0 | 61.8 |
%비율 | 간 | 지방 | |
ND | 126.7 | 28.2 | |
HF | 100.0 | 100.0 | |
ID1215B | 250mg/kg | 81.4 | 68.6 |
500mg/kg | 86.0 | 69.5 | |
750mg/kg | 75.6 | 68.6 |
%비율 | 콜레스테롤 | 중성지방 | 유리지방산 | |
ND | 55.9 | 90.0 | 92.9 | |
HF | 100.0 | 100.0 | 100.0 | |
ID1215B | 250mg/kg | 97.9 | 69.9 | 92.9 |
500mg/kg | 107.1 | 57.4 | 92.9 | |
750mg/kg | 96.5 | 52.7 | 85.7 |
그룹 | 용량 (mg/kg) | 알부민 (U/L) | ALP (mg/dL) | ALT (mg/dL) | AST (mg/dL) | 빌리루빈 (mg/dL) | 크레아틴 (mg/dL) | BUN (mg/dL) |
ND | 0 | 3.3± 0.37 |
171.1± 18.9 |
102.4± 27.8 |
241.4± 57.7 |
0.65± 0.10 |
0.42±0.06 | 30.9± 4.58 |
HF | 0 | 3.6± 0.06 |
138.3± 17.4 |
98.0± 23.7 |
259.8± 49.3 |
0.73± 0.17 |
0.47±0.03 | 26.5± 5.81 |
ID1215B | 250 | 3.7± 0.21 |
128.1± 24.5 |
61.4± 23.9* |
182.8± 72.5* |
0.64± 0.20 |
0.45±0.07 | 21.6± 3.38 |
500 | 3.7± 0.35 |
101.9± 15.8* |
47.9± 8.9* |
139.5± 34.5* |
0.59± 0.11 |
0.45±0.07 | 25.9± 4.82 |
|
750 | 3.9± 0.14* |
107.6± 8.9* |
58.4± 23.1* |
159.5± 55.9* |
0.78± 0.16 |
0.42±0.06 | 25.0± 3.12 |
그룹 | 용량 (mg/kg) | 알부민(g/dL) | ALP (U/L) | ALT (U/L) | AST (U/L) |
빌리루빈 (mg/dL) | 크레아틴 (mg/dL) | BUN (mg/dL) |
Vehicle | 0 | 2.6± 0.1 |
184± 58.7 |
41± 13.2 |
67± 6.4 |
0.54± 0.1 |
0.33± 0.06 |
17.5± 1.6 |
ID1215B | 1000 | 2.7± 0.07 |
166± 45.1 |
42± 10.2 |
62± 6.0 |
0.77± 0.4 |
0.36± 0.06 |
16.8± 1.2 |
2000 | 2.9± 0.35 |
171± 34.2 |
45± 7.4 |
67± 9.3 |
0.62± 0.1 |
0.29± 0.05 |
17.8± 3.4 |
|
3000 | 2.7± 0.07 |
144± 22.3 |
45± 15.3 |
67± 13.2 |
0.58± 0.1 |
0.28± 0.07 |
16.3± 1.0 |
Claims (4)
- 대잎둥굴레 (Polygonatum falcatum) 또는 층층갈고리둥굴레 (Polygonatum sibiricum)인 둥굴레속 식물의 물, 에탄올, 주정, 메탄올, 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol), 아세톤, 에테르, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, 헥산, 시클로헥산, 석유에테르(petroleum ether), 디에틸에테르, 벤젠으로 이루어진 군에서 선택된 하나 이상의 용매 추출물을 함유하는 비만, 비만 합병증 및 대사증후군으로 이루어진 군에서 선택된 하나 이상의 질환의 예방 및 치료용 약학적 조성물.
- 삭제
- 대잎둥굴레 (Polygonatum falcatum) 또는 층층갈고리둥굴레 (Polygonatum sibiricum)인 둥굴레속 식물의 물, 에탄올, 주정, 메탄올, 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol), 아세톤, 에테르, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, 헥산, 시클로헥산, 석유에테르(petroleum ether), 디에틸에테르, 벤젠으로 이루어진 군에서 선택된 하나이상의 용매 추출물을 함유하는 비만, 비만 합병증 및 대사증후군으로 이루어진 군에서 선택된 하나 이상의 질환의 예방 및 완화용 식품 조성물.
- 삭제
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011800175142A CN102844042A (zh) | 2010-04-09 | 2011-04-08 | 镰刀黄精或狭叶黄精提取物的新用途 |
PCT/KR2011/002491 WO2011126342A2 (ko) | 2010-04-09 | 2011-04-08 | 대잎둥굴레 또는 층층갈고리둥굴레 추출물의 신규한 용도 |
JP2013503700A JP5799082B2 (ja) | 2010-04-09 | 2011-04-08 | 眞黄精又は黄精抽出物の新規な用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100032921 | 2010-04-09 | ||
KR20100032921 | 2010-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101018531B1 true KR101018531B1 (ko) | 2011-03-11 |
Family
ID=43938249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100095987A KR101018531B1 (ko) | 2010-04-09 | 2010-10-01 | 대잎둥굴레 또는 층층갈고리둥굴레 추출물을 유효성분으로 포함하는 비만 또는 대사 증후군 예방 및 치료용 조성물 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5799082B2 (ko) |
KR (1) | KR101018531B1 (ko) |
CN (1) | CN102844042A (ko) |
WO (1) | WO2011126342A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104324228A (zh) * | 2014-11-26 | 2015-02-04 | 安徽省旌德博仕达农业科技有限公司 | 一种黄精含片及其制备方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6134125B2 (ja) * | 2011-11-18 | 2017-05-24 | 株式会社紀文食品 | 逆転写酵素阻害剤およびキット |
CN110537467A (zh) * | 2019-09-25 | 2019-12-06 | 贵州百灵企业集团制药股份有限公司 | 一种滇黄精种子大棚育苗方法 |
CN112870305A (zh) * | 2021-02-26 | 2021-06-01 | 云南彝风堂医疗科技有限公司 | 一种治疗痛风的药物组合物、制剂及其制备方法和应用 |
CN115707782A (zh) * | 2022-08-10 | 2023-02-21 | 贵州省植物园(贵州省园林科学研究所、贵州省植物研究所) | 多花黄精致病真菌筛选方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1939475A (zh) * | 2006-09-21 | 2007-04-04 | 张志祥 | 枸杞葛根胶囊及其制备工艺 |
CN101352539A (zh) * | 2008-09-05 | 2009-01-28 | 何进爱 | 一种治疗糖尿病的中药组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100416650B1 (ko) * | 2000-10-19 | 2004-02-05 | 신동수 | 둥굴레 추출물과 그를 함유한 혈장 지질 및 혈당 강하용조성물 |
KR20020033336A (ko) * | 2000-10-30 | 2002-05-06 | 박선민 | 둥굴레 뿌리 추출물을 함유하는 식품 조성물 |
JP2002241293A (ja) * | 2001-02-13 | 2002-08-28 | Ichimaru Pharcos Co Ltd | メイラード反応阻害剤 |
KR100815867B1 (ko) * | 2005-12-06 | 2008-03-21 | 대구한의대학교산학협력단 | 황정 추출물을 유효성분으로 포함하는 면역증강용약학조성물 |
-
2010
- 2010-10-01 KR KR1020100095987A patent/KR101018531B1/ko active IP Right Grant
-
2011
- 2011-04-08 CN CN2011800175142A patent/CN102844042A/zh active Pending
- 2011-04-08 WO PCT/KR2011/002491 patent/WO2011126342A2/ko active Application Filing
- 2011-04-08 JP JP2013503700A patent/JP5799082B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1939475A (zh) * | 2006-09-21 | 2007-04-04 | 张志祥 | 枸杞葛根胶囊及其制备工艺 |
CN101352539A (zh) * | 2008-09-05 | 2009-01-28 | 何进爱 | 一种治疗糖尿病的中药组合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104324228A (zh) * | 2014-11-26 | 2015-02-04 | 安徽省旌德博仕达农业科技有限公司 | 一种黄精含片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2013523810A (ja) | 2013-06-17 |
JP5799082B2 (ja) | 2015-10-21 |
WO2011126342A2 (ko) | 2011-10-13 |
CN102844042A (zh) | 2012-12-26 |
WO2011126342A3 (ko) | 2012-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Savina et al. | Chemical composition and toxicological evaluation of the aqueous leaf extracts of Plectranthus amboinicus Lour. Spreng | |
KR20130128349A (ko) | 캠페리아 파비플로라 추출물 또는 플라본계 화합물을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물 | |
KR101018531B1 (ko) | 대잎둥굴레 또는 층층갈고리둥굴레 추출물을 유효성분으로 포함하는 비만 또는 대사 증후군 예방 및 치료용 조성물 | |
Qu et al. | 18α-Glycyrrhizin induces apoptosis and suppresses activation of rat hepatic stellate cells | |
Mo et al. | Ginsenoside Rg1 ameliorates palmitic acid-induced insulin resistance in HepG2 cells in association with modulating Akt and JNK activity | |
Chen et al. | Polysaccharides from Citrus grandis L. Osbeck suppress inflammation and relieve chronic pharyngitis | |
Xiao et al. | Rice bran phenolic extract confers protective effects against alcoholic liver disease in mice by alleviating mitochondrial dysfunction via the PGC-1α-TFAM pathway mediated by microRNA-494-3p | |
KR101760512B1 (ko) | 혼합 생약 추출물을 포함하는 만성 염증성 질환의 예방, 치료 또는 개선용 조성물 | |
KR101441609B1 (ko) | 삼채 추출물을 유효성분으로 포함하는 대사성 질환 예방 및 치료용 조성물 | |
JP2007526914A (ja) | 魚腥草と徳利苺の実の抽出物とそれらのアレルギー疾患予防及び治療用組成物(ExtractsofHouttuyniacordataandRubuscoreanusandtheircompositionforpreventingandtreatingallergicdiseases) | |
US10507224B2 (en) | Composition including kirenol or siegesbeckia herba extract for muscle function improvement or exercise ability enhancement | |
US20110300246A1 (en) | Herbal Extracts for Treatment of Diabetic Complications and Oxidative Stress | |
KR20070069566A (ko) | 티모사포닌 a―ⅲ가 함유된 조성물의 용도 및 이의제조방법 | |
KR101135132B1 (ko) | 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물의 신규한 용도 | |
KR101160088B1 (ko) | 알코올성 지방간과 고지혈증 억제 및 숙취 억제 조성물 | |
Jia et al. | Eleutheroside E from pre-treatment of Acanthopanax senticosus (Rupr. etMaxim.) Harms ameliorates high-altitude-induced heart injury by regulating NLRP3 inflammasome-mediated pyroptosis via NLRP3/caspase-1 pathway | |
Zhu et al. | Evaluation of the anti-inflammatory material basis of Lagotis brachystachya in HepG2 and THP-1ácells | |
KR100824365B1 (ko) | 오죽 추출물, 분획물 또는 이로부터 분리한 화합물을 포함하는 당뇨병 합병증 예방 또는 치료용 조성물 | |
KR102249535B1 (ko) | 알카닌을 유효성분으로 포함하는 대사성 질환용 조성물 | |
KR101157028B1 (ko) | 호모이소플라바논을 유효성분으로 함유하는 비만 또는 대사증후군 예방 및 치료용 조성물 | |
US20220226406A1 (en) | Composition containing extract of cannabis sativa for preventing or treating metabolic syndrome-related disease | |
KR102406795B1 (ko) | 호장근 및 계심 추출물을 포함하는 인지기능 장애의 예방, 개선 또는 치료용 조성물 | |
KR102627493B1 (ko) | 패 추출물을 포함하는 트리메틸틴 매개 신경변성 예방, 개선 또는 치료용 조성물 내지 이의 용도 | |
Goel et al. | Estimation of anti-obesity potential of Tribulus terrestris in Wistar rats (high fat diet inducted obesity) | |
KR102261920B1 (ko) | 황기 및 지치 복합 추출물을 유효성분으로 포함하는 간 손상 예방 및 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131227 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150217 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151130 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170207 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180105 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190214 Year of fee payment: 9 |